Dr. Salkeni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8613 Route 29
200
Fairfax, VA 22031Phone+1 571-350-8400Fax+1 703-940-8746
Summary
- Dr. Mohamad Adham Salkeni is an oncologist in Fairfax, VA. Specializes in developmental therapeutics and early phase clinical trials. Affiliated with Virginia Cancer Specialists, and with NEXT Oncology.
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2009 - 2012
SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 2006 - 2010
Damascus University Faculty of MedicineClass of 2004
Certifications & Licensure
VA State Medical License 2022 - 2026
WV State Medical License 2012 - 2025
PA State Medical License 2020 - 2022
OH State Medical License 2010 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
- Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Publications & Presentations
PubMed
- Advanced Granulosa Cell Tumors of the Ovary: A Review with a Focus on Current and Novel Therapeutic Approaches.Mohamad A Salkeni, Sarah Shin, Naoko Takebe, Sally Stevens, Alice Chen
Journal of Immunotherapy and Precision Oncology. 2024-11-01 - Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero
Breast Cancer Research. 2024-05-24 - NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero
Breast Cancer Research. 2024-04-22
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
